Expression of Activated Epidermal Growth Factor Receptors, Ras-Guanosine Triphosphate, and Mitogen-activated Protein Kinase in Human Glioblastoma Multiforme Specimens

Expression of Activated Epidermal Growth Factor Receptors, Ras-Guanosine Triphosphate, and... AbstractOBJECTIVE:Amplification of the epidermal growth factor receptor (EGFR) is a common event in the molecular pathogenesis of high-grade astrocytic tumors, occurring in 50% of glioblastoma multiforme (GBM) cases. A subset of GBMs also express a constitutively phosphorylated truncated receptor (EGFRvlll). Expression of transfected EGFRvlll in cells has been reported to activate the Ras-mitogen-activated protein kinase pathway and to provide a growth advantage. Novel therapeutic agents targeting signal transduction pathways are entering early clinical trials; determination of which GBMs express EGFRvlll might help identify patients who might benefit from these biological agents.METHODS:A cohort of 15 flash-frozen surgical specimens (12 GBMs, 2 gliosarcomas, and 1 adult low-grade glioma) were evaluated for EGFR and EGFRvlll expression and for EGFR activation status using immunohistochemical (IHC) analysis, Western blotting, and reverse transcription-polymerase chain reaction assays. Levels of activated Ras-guanosine triphosphate were measured using a nonradioactive luciferase-based technique. Mitogen- activated protein kinase activation was determined using a myelin basic protein assay. IHC analysis was performed on paraffin-embedded, formalin-fixed, pathological specimens. Normal control samples included white matter specimens distal to tumors (n = 5), a sample obtained during a lobectomy for treatment of epilepsy (n = 1), and cultured fetal human astrocytes (n = 1).RESULTS:We demonstrated higher levels of activated Ras and mitogen-activated protein kinase in GBM specimens, compared with normal brain tissue or the low-grade glioma. There was a very good correlation between results obtained using specialized molecular techniques and those obtained using routine IHC techniques. Screening for EGFRvlll expression may be of prognostic importance, because patients with EGFRvlll-positive tumors exhibited shorter life expectancies (mean survival time for patients with EGFRvlll-positive tumors, 4.5 ± 0.6 mo; mean survival time for patients with EGFRvlll-negative tumors, 11.2 ± 0.9 mo).CONCLUSION:We demonstrated that routine IHC techniques using commercially available antibodies are capable of identifying which GBM specimens express EGFRvlll and whether the EGFRs are activated. Such a molecular classification of GBMs might allow us to determine which patients might benefit from biologically targeted therapies. In addition, characterization of specimens with respect to their EGFRvlll status seems to be of prognostic value. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Expression of Activated Epidermal Growth Factor Receptors, Ras-Guanosine Triphosphate, and Mitogen-activated Protein Kinase in Human Glioblastoma Multiforme Specimens

Expression of Activated Epidermal Growth Factor Receptors, Ras-Guanosine Triphosphate, and Mitogen-activated Protein Kinase in Human Glioblastoma Multiforme Specimens

Expression of Activated Epidermal Growth Factor Receptors, Ras-Guanosine Triphosphate, and Mitogen-activated Protein Kinase in Human Glioblastoma Multiforme Specimens Matthias M. Feldkamp, M.D., Prateek Lala, B.Sc., Nelson Lau, B.Sc., Luba Roncari, M.Sc., Abhijit Guha, M.D. Samuel Lunenfeld Research Institute (M M F, PL, NL, LR, A C ), M o u n t Sinai H osp ita l; D iv is io n o f N eurosurgery (M M F , A C ), T o ro n to W estern H osp ita l, U n ive rsity H ea lth N e tw o rk , and U n iv e rs ity o f T o ro n to ; and D e p a rtm e n t o f Surgical O n c o lo g y (AC), O n ta rio C ancer Institute/Princess M argaret H ospita l, T oronto, O n ta rio , Canada O B JEC T IV E: Am plification of the epidermal growth factor receptor (EG FR ) is a common event in the molecular pathogenesis of high-grade astrocytic tumors, occurring in 5 0 % of glioblastoma m ultiforme (G B M ) cases. A subset of G B M s also express a constitutively phosphorylated truncated receptor (E G F R v lll). Expression of transfected E G F R v lll in cells has been reported to activate the Ras-mitogen-activated protein kinase pathway and to provide a growth advantage. Novel therapeutic agents targeting signal transduction pathways are entering early clinical trials; determination of which G B M s express E G F R v lll might help identify patients who might benefit from these biological agents. M ET H O D S: A cohort of 15 flash-frozen surgical specimens (12 G BM s, 2 gliosarcomas, and 1 adult low-grade glioma) were evaluated for EG FR and E G F R v lll expression and for EG FR activation status using immunohistochemical (IH C ) analysis, W estern blotting, and reverse transcription-polymerase chain reaction assays. Levels of activated Ras-guanosine triphosphate were measured using a nonradioactive luciferase-based technique. Mitogen- activated protein kinase activation was determined using a myelin basic protein assay. IH C analysis was performed on paraffin-embedded, formalin-fixed,...
Loading next page...
 
/lp/ou_press/expression-of-activated-epidermal-growth-factor-receptors-ras-qi4pBE1xZ9
Publisher
Congress of Neurological Surgeons
Copyright
© Published by Oxford University Press.
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1097/00006123-199912000-00034
Publisher site
See Article on Publisher Site

Abstract

AbstractOBJECTIVE:Amplification of the epidermal growth factor receptor (EGFR) is a common event in the molecular pathogenesis of high-grade astrocytic tumors, occurring in 50% of glioblastoma multiforme (GBM) cases. A subset of GBMs also express a constitutively phosphorylated truncated receptor (EGFRvlll). Expression of transfected EGFRvlll in cells has been reported to activate the Ras-mitogen-activated protein kinase pathway and to provide a growth advantage. Novel therapeutic agents targeting signal transduction pathways are entering early clinical trials; determination of which GBMs express EGFRvlll might help identify patients who might benefit from these biological agents.METHODS:A cohort of 15 flash-frozen surgical specimens (12 GBMs, 2 gliosarcomas, and 1 adult low-grade glioma) were evaluated for EGFR and EGFRvlll expression and for EGFR activation status using immunohistochemical (IHC) analysis, Western blotting, and reverse transcription-polymerase chain reaction assays. Levels of activated Ras-guanosine triphosphate were measured using a nonradioactive luciferase-based technique. Mitogen- activated protein kinase activation was determined using a myelin basic protein assay. IHC analysis was performed on paraffin-embedded, formalin-fixed, pathological specimens. Normal control samples included white matter specimens distal to tumors (n = 5), a sample obtained during a lobectomy for treatment of epilepsy (n = 1), and cultured fetal human astrocytes (n = 1).RESULTS:We demonstrated higher levels of activated Ras and mitogen-activated protein kinase in GBM specimens, compared with normal brain tissue or the low-grade glioma. There was a very good correlation between results obtained using specialized molecular techniques and those obtained using routine IHC techniques. Screening for EGFRvlll expression may be of prognostic importance, because patients with EGFRvlll-positive tumors exhibited shorter life expectancies (mean survival time for patients with EGFRvlll-positive tumors, 4.5 ± 0.6 mo; mean survival time for patients with EGFRvlll-negative tumors, 11.2 ± 0.9 mo).CONCLUSION:We demonstrated that routine IHC techniques using commercially available antibodies are capable of identifying which GBM specimens express EGFRvlll and whether the EGFRs are activated. Such a molecular classification of GBMs might allow us to determine which patients might benefit from biologically targeted therapies. In addition, characterization of specimens with respect to their EGFRvlll status seems to be of prognostic value.

Journal

NeurosurgeryOxford University Press

Published: Dec 1, 1999

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial